Completed × INDUSTRY × Carcinoma, Transitional Cell × Clear all
NCT03126110 2025-08-14

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Incyte Corporation

Phase 1/2 Completed
145 enrolled 47 charts
NCT02635672 2024-11-15

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

Vincerx Pharma, Inc.

Phase 1 Completed
110 enrolled
NCT03752398 2024-07-05

DUET-3

Xencor, Inc.

Phase 1 Completed
198 enrolled